Literature DB >> 3110375

Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L-[11C]deprenyl.

C D Arnett, J S Fowler, R R MacGregor, D J Schlyer, A P Wolf, B Långström, C Halldin.   

Abstract

The distribution of carbon-11-labeled L-deprenyl, an irreversible inhibitor of monoamine oxidase type B (MAO-B), was determined in the baboon brain by positron emission tomography. The irreversible blood-to-brain transfer constant (influx constant, Ki) was measured using a complete metabolite-corrected arterial plasma concentration curve. This influx constant was used as a measure of functional enzyme activity for sequential determinations of MAO-B recovery following a single high dose of unlabeled L-deprenyl. The half-life for turnover of MAO-B was thus determined to be 30 days. Using appropriate irreversible inhibitors, this procedure should be generally useful for determining enzyme turnover rates in any organ in vivo and can be applied to some human studies as well.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3110375     DOI: 10.1111/j.1471-4159.1987.tb02895.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  16 in total

Review 1.  Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics (Part II).

Authors:  L L Ponto; J A Ponto
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

Review 2.  Approaches to the design of biochemical probes for positron emission tomography.

Authors:  J R Barrio
Journal:  Neurochem Res       Date:  1991-09       Impact factor: 3.996

Review 3.  Tracers for metabolic imaging of brain and heart. Radiochemistry and radiopharmacology.

Authors:  G Stöcklin
Journal:  Eur J Nucl Med       Date:  1992

Review 4.  PET: a biological imaging technique.

Authors:  M E Phelps
Journal:  Neurochem Res       Date:  1991-09       Impact factor: 3.996

5.  A comparison of drug-seeking behavior maintained by D-amphetamine, L-deprenyl (selegiline), and D-deprenyl under a second-order schedule in squirrel monkeys.

Authors:  Sevil Yasar; József Gaál; Leigh V Panlilio; Zuzana Justinova; Szecsö V Molnár; Godfrey H Redhi; Charles W Schindler
Journal:  Psychopharmacology (Berl)       Date:  2005-11-15       Impact factor: 4.530

6.  Synthesis and in vivo studies of a specific monoamine oxidase B inhibitor: 5-[4-(benzyloxy)phenyl]-3-(2-cyanoethyl)- 1,3,4-oxadiazol-[11C]-2(3H)-one.

Authors:  S Bernard; C Fuseau; L Schmid; R Milcent; C Crouzel
Journal:  Eur J Nucl Med       Date:  1996-02

7.  MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding.

Authors:  Allan K Hansen; David J Brooks; Per Borghammer
Journal:  Mol Imaging Biol       Date:  2018-06       Impact factor: 3.488

8.  Inhibition of monoamine oxidases by haloperidol and its metabolites: pharmacological implications for the chemotherapy of schizophrenia.

Authors:  J Fang; P H Yu; J W Gorrod; A A Boulton
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

9.  Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327.

Authors:  C J Bench; G W Price; A A Lammertsma; J C Cremer; S K Luthra; D Turton; R J Dolan; R Kettler; J Dingemanse; M Da Prada
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion.

Authors:  Debra S Harris; Thomas Everhart; Peyton Jacob; Emil Lin; John E Mendelson; Reese T Jones
Journal:  BMC Clin Pharmacol       Date:  2009-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.